rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Redmile Group, LLC

10% owner

Company insider

Files Form 4 as: 10% owner, Attovia Therapeutics; Director, Atara Biotherapeutics; Director and 10% owner, Fate Therapeutics; 10% owner, ADC Therapeutics SA; Director and 10% owner, Shattuck Labs; Director and 10% owner, IGM Biosciences; Director and 10% owner, Augmedix; Director and 10% owner, Absci.

Every Form 4 they filed

In numbers

Trades disclosed
189
Buys
27
Sells
5
Bought
$218.7M
Sold
$23.2M
Companies
27
Companies where not an officer
27
First trade
26 Aug 2015
Last trade
6 Aug 2026
Last filed
7 Aug 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
ATTO Attovia Therapeutics10% owner · Biotechnology · last 6 Aug 20261 buy · 0 sells
ATRA Atara BiotherapeuticsDirector · Biotechnology · last 22 Jul 20260 buys · 0 sells
FATE Fate TherapeuticsDirector, 10% owner · Biotechnology · last 12 Jun 20263 buys · 0 sells
ADCT ADC Therapeutics SA10% owner · Biotechnology · last 2 Apr 20260 buys · 3 sells
STTK Shattuck LabsDirector, 10% owner · Biotechnology · last 14 Jul 20250 buys · 0 sells
IGM BiosciencesDirector, 10% owner · last 30 Jun 20257 buys · 1 sell
AugmedixDirector, 10% owner · last 14 Jun 20241 buy · 0 sells
ABSI AbsciDirector, 10% owner · Life-science tools · last 12 Jun 20241 buy · 0 sells
MedAvail HoldingsDirector, 10% owner · last 16 Jun 20230 buys · 0 sells
ZYME Zymeworks10% owner · Biotechnology · last 13 Oct 20221 buy · 0 sells
Science 37 HoldingsDirector, 10% owner · last 23 May 20220 buys · 0 sells
TRDA Entrada Therapeutics10% owner · Biotechnology · last 2 Nov 20211 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
301Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
6 Aug 2026filed 7 Aug 2026ATTO Attovia TherapeuticsBiotechnologySEC FORM 4 Code C—782,854filing
6 Aug 2026filed 7 Aug 2026ATTO Attovia TherapeuticsBiotechnologySEC FORM 4 Bought$3.4M200,000 at $17.00filing
6 Aug 2026filed 7 Aug 2026ATTO Attovia TherapeuticsBiotechnologySEC FORM 4 Bought$6.8M400,000 at $17.00filing
6 Aug 2026filed 7 Aug 2026ATTO Attovia Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—782,854filing
22 Jul 2026filed 24 Jul 2026ATRA Atara BiotherapeuticsBiotechnologySEC FORM 4 Code M—195,211filing
22 Jul 2026filed 24 Jul 2026ATRA Atara BiotherapeuticsBiotechnologySEC FORM 4 Code F—60filing
22 Jul 2026filed 24 Jul 2026ATRA Atara Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—101,089 at $0.00filing
22 Jul 2026filed 24 Jul 2026ATRA Atara Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—101,089 at $0.00filing
22 Jul 2026filed 24 Jul 2026ATRA Atara Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—38,735 at $0.00filing
22 Jul 2026filed 24 Jul 2026ATRA Atara Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—55,387 at $0.00filing
22 Jul 2026filed 24 Jul 2026ATRA Atara Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—38,735 at $0.00filing
22 Jul 2026filed 24 Jul 2026ATRA Atara Biotherapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—55,387 at $0.00filing
22 Jul 2026filed 24 Jul 2026ATRA Atara BiotherapeuticsBiotechnologySEC FORM 4 Code M—195,211filing
22 Jul 2026filed 24 Jul 2026ATRA Atara BiotherapeuticsBiotechnologySEC FORM 4 Code F—60filing
12 Jun 2026filed 15 Jun 2026FATE Fate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—87,900 at $0.00filing
12 Jun 2026filed 15 Jun 2026FATE Fate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—87,900 at $0.00filing
20 Apr 2026filed 23 Apr 2026FATE Fate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code J—266,280 at $0.00filing
20 Apr 2026filed 23 Apr 2026FATE Fate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code J—266,280 at $0.00filing
20 Apr 2026filed 23 Apr 2026FATE Fate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code J—266,280 at $0.00filing
20 Apr 2026filed 23 Apr 2026FATE Fate Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code J—266,280 at $0.00filing

News

Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) versus ADC Therapeutics (NYSE:ADCT)ADCT · dailypolitical.com · 8 Oct 2026

0 headlines in the last 90 days name Redmile Group, LLC; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.

Sectors

Health Care13
Not placed19

Buys in green, sells in red, by the company’s sector.

Related people

Tao FuPresident and CEO · President and CEO at Attovia Therapeutics, filing Form 4 there in the last year
Steven ChanChief Financial Officer · Chief Financial Officer at Attovia Therapeutics, filing Form 4 there in the last year
Brian N. CherryDirector · Director at Atara Biotherapeutics, filing Form 4 there in the last year
Colin WalshDirector · Director at Attovia Therapeutics, filing Form 4 there in the last year
GOLDMAN SACHS GROUP INCOther role · Other at Attovia Therapeutics, filing Form 4 there in the last year
Adam SchayowitzEVP, Head of R&D · Also traded ZYME in the last 90 days
MPM BioVentures 2014, L.P.10% owner · Also traded TRDA in the last 90 days
MPM BIOVENTURES 2018, L.P.10% owner · Also traded TRDA in the last 90 days